SynthesisMovement disorders clinical practice2026
Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review & Meta-Analysis.
Synthesis in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Implementation of a novel strategy to increase participation of Black and Hispanic people in parkinsonism research.Journal of Parkinson's disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThere is a historic underrepresentation of non-White participants in Parkinson's Disease (PD) research, although this has not been explored in trials for potential disease-modifying therapies.
objectiveTo evaluate the representation of racial/ethnic minority patients enrolled in double-blind, randomized, placebo-controlled clinical trials (DBRCTs) for PD.
methodsA systematic search of four electronic databases was performed. DBRCTs evaluating pharmacological therapies for disease modification in PD were included. Data extraction followed PRISMA guidelines. We computed demographic data with pooled prevalence and 95% confidence intervals (CIs).
resultsAmong 37 DBRCTs and 11,022 patients, 19 studies (51.4%) reported race/ethnicity, being 1.4% Asian, 0.19% Black, and 0.17% Hispanic. Pooled prevalence of participants identified as White in clinical trials was 98% (CI 0.97-0.99, P < 0.001).
conclusionRacial and ethnic minorities were disproportionately underrepresented in DBRCTs for potential disease-modifying therapies for PD. Additional efforts are required to increase the racial and ethnic representation in such studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.